FindTrial
Sign In

Immunogenicity and Safety of the DTaP-IPV (sanofi Pasteur Kitasato) Combined Vaccine (DD-687) given subcutaneously as a three-dose primary and booster vaccination versus commercially available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in Japan

Immunogenicity and Safety of the DTaP-IPV (sanofi Pasteur Kitasato) Combined Vaccine (DD-687) given subcutaneously as a three-dose primary and booster vaccination versus commercially available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in Japan

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221313
Enrollment
374
Registered
2010-11-17
Start date
2010-11-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis of pertussis, diphtheria, tetanus, and poliomyelitis infection.

Interventions

investigational material(s) Generic name etc : DD-687 INN of investigational material : Therapeutic category code : 631 Vaccines Dosage and Administration for Investigational material : Subcutaneous

Sponsors

DAIICHISANKYO Co.,Ltd., Sanofi Aventis KK
Lead Sponsor
The Kitasato Institute, Sanofi Pasteur KK, Sanofi Pasteur SA
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: starting at 3-68 (recommended 3-8) months of age

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Immunogenicity anti-Polio 1, 2 and 3 antibody titers—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026